This article has been reproduced from the NHS website.

“Millions of women who take HRT pills may face a greater risk of Alzheimer’s,” warns the Mail Online.

A study identified all postmenopausal women in Finland who’d been diagnosed with Alzheimer’s disease over a 14-year period. It compared their use of HRT (hormone replacement therapy) with a group of postmenopausal women without the disease.

Researchers found that those with Alzheimer’s were slightly more likely to have used HRT pills or patches than women without Alzheimer’s.

There was little difference with use of vaginal HRT (oestrogen gel).

Researchers said that, if the raised risk of HRT was confirmed, it would mean an additional 9 to 18 cases of Alzheimer’s disease out of every 10,000 women aged 70 to 80 each year.

Previous research looking for a link between Alzheimer’s disease and HRT has had conflicting results. Some studies suggest HRT has a protective effect, while others do not, or suggest it might depend what age you are when you take it.

This is one of the largest studies looking for a link. But it does not prove that HRT directly increases risk of Alzheimer’s disease. It’s not possible to take account of the other possible risk factors, such as family history and lifestyle.

It’s also important to realise that even if there is a direct link, any increase in risk is very small. The benefits of HRT in combating menopausal symptoms may still outweigh this small risk.

Where did the story come from?

Researchers who carried out the study came from the University of Helsinki, EPID Research Oy and the National Institute for Health and Welfare, all in Finland. The study was funded by Helsinki University Hospital and the Jane and Aatos Erkko Foundation.

It was published in the peer-reviewed British Medical Journal on an open-access basis, and is free to read online.

The report was handled with caution by most of the UK media, with reports carrying reassurances from doctors and other experts that the risk, if real, is low.

The Mail Online had the most alarming coverage, rounding up the numbers to suggest that “HRT was linked with up to a 20 per cent increase in Alzheimer’s disease risk” – only true for specific groups of women in the study.

What kind of research was this?

This was a case control study. This type of study looks at people with and people without a disease (in this case Alzheimer’s disease) to compare the potential risk from an exposure (HRT in this case).

But it can’t prove that a risk factor (HRT) causes the outcome (Alzheimer’s disease) as these studies are observational, and other things may differ between the 2 compared groups of people.

What did the research involve?

Researchers identified 84,739 postmenopausal women in Finland who had been diagnosed with Alzheimer’s disease between 1999 and 2013, using a national register.

They then identified 84,739 women without Alzheimer’s disease, matched by age and district, to act as a control group.

Using a Finnish drug registry, they identified whether women had taken HRT, and if so:

  • which type of HRT
  • when they started taking it
  • how long they’d taken it

Researchers then calculated whether women with Alzheimer’s disease were more likely to have taken HRT than women in the control group.

Because of limits in the data available, researchers were not able to account for possible confounding factors such as:

  • a family history of Alzheimer’s disease
  • high blood pressure
  • smoking
  • cholesterol levels

They reported results separately for:

  • women who had started HRT before age 60
  • women who had started HRT aged 60 or over
  • different types of HRT (oestrogen alone, or combined oestrogen and progestogen, and systemic or vaginal HRT)
  • different lengths of treatment

Researchers then looked to see whether any of these affected the results.

What were the basic results?

Women with Alzheimer’s disease were slightly more likely to have used HRT pills or patches (18.6% compared with 17% of women without Alzheimer’s disease).

Use of vaginal oestrogen alone was little different (12.7% of women with Alzheimer’s disease vs. 13.2% without).

Before age 60

For women who had started HRT before the age of 60, use of:

  • oestrogen-only HRT was linked to a 6% increased risk of Alzheimer’s disease (odds ratio (OR) 1.06, 95% confidence interval (CI) 1.01 to 1.12)
  • combined oestrogen and progestogen HRT was linked to a 14% increase in risk (OR 1.14, 95% CI 1.09 to 1.19)

60 or older

For women who had started HRT aged 60 or over:

  • oestrogen-only HRT was linked to a 15% increased risk of Alzheimer’s disease (OR 1.15, 95%CI 1.06 to 1.25)
  • combined HRT was linked to a 23% increased risk (OR 1.23, 95% CI 1.14 to 1.32)

Vaginal oestrogen

Using vaginal oestrogen alone was not linked to risk of Alzheimer’s disease (OR 0.99, 95% CI 0.96 to 1.01).

Types of progestogen

Different types of progestogen made no difference to the overall risk of developing Alzheimer’s disease.

Length of time taking HRT

Using HRT for 10 years or more was linked to a higher risk of Alzheimer’s disease in women who had started taking it under 60 (OR 1.20, 95% CI 1.13 to 1.26).

The age at which women started taking HRT did not make a big difference to their overall risk of Alzheimer’s disease.

How did the researchers interpret the results?

The researchers said: “Hormone therapy users should be informed of a possible risk of the disease with prolonged use of Alzheimer’s disease, even though the absolute risk elevations are small.”


Headlines about an increase in risk of Alzheimer’s for women taking HRT are alarming.

It’s important to remember that this study does not show that HRT directly increases the risk of Alzheimer’s disease. It shows a link between HRT use and a small increase in risk, which appears to be stronger for women who use HRT in the long term.

However, there are a couple of important things to note.

First, the study cannot prove that HRT is directly responsible for this small risk increase.

The study was unable to take account of other factors that could affect risk of Alzheimer’s disease. These include family history, blood pressure and smoking.

Second, if there is a direct risk increase, it seems to be small. The absolute difference in terms of women with and without Alzheimer’s who’d used HRT was small, and some of the risk associations only just reached statistical significance.

HRT is a helpful treatment for many women with troublesome menopausal symptoms. This study does not mean women should stop taking it. The benefits may still outweigh any risk of Alzheimer’s.

There are things you can do to help reduce your risk of Alzheimer’s disease, although there are no guarantees as so many different factors are likely to be involved. Find out about preventing Alzheimer’s disease.

Analysis by Bazian 
Edited by NHS Website